Department of Obstetrics, Key Laboratory of Birth Defects and Related Disease of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second Hospital, Sichuan University, Chengdu, 610041, China.
Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai, 200438, China.
Nat Commun. 2023 Mar 28;14(1):1727. doi: 10.1038/s41467-023-37411-1.
By lacking de novo purine biosynthesis enzymes, Plasmodium falciparum requires purine nucleoside uptake from host cells. The indispensable nucleoside transporter ENT1 of P. falciparum facilitates nucleoside uptake in the asexual blood stage. Specific inhibitors of PfENT1 prevent the proliferation of P. falciparum at submicromolar concentrations. However, the substrate recognition and inhibitory mechanism of PfENT1 are still elusive. Here, we report cryo-EM structures of PfENT1 in apo, inosine-bound, and inhibitor-bound states. Together with in vitro binding and uptake assays, we identify that inosine is the primary substrate of PfENT1 and that the inosine-binding site is located in the central cavity of PfENT1. The endofacial inhibitor GSK4 occupies the orthosteric site of PfENT1 and explores the allosteric site to block the conformational change of PfENT1. Furthermore, we propose a general "rocker switch" alternating access cycle for ENT transporters. Understanding the substrate recognition and inhibitory mechanisms of PfENT1 will greatly facilitate future efforts in the rational design of antimalarial drugs.
由于缺乏从头合成嘌呤的酶,恶性疟原虫需要从宿主细胞中摄取嘌呤核苷。恶性疟原虫必需的核苷转运蛋白 ENT1 有助于无性血期的核苷摄取。PfENT1 的特异性抑制剂以亚微摩尔浓度阻止恶性疟原虫的增殖。然而,PfENT1 的底物识别和抑制机制仍不清楚。在这里,我们报告了 PfENT1 在apo、肌苷结合和抑制剂结合状态下的冷冻电镜结构。结合体外结合和摄取实验,我们确定肌苷是 PfENT1 的主要底物,肌苷结合位点位于 PfENT1 的中央腔中。内表面抑制剂 GSK4 占据 PfENT1 的正位点,并探索变构点以阻止 PfENT1 的构象变化。此外,我们提出了一个通用的“摇臂开关”交替访问循环,用于 ENT 转运蛋白。了解 PfENT1 的底物识别和抑制机制将极大地促进未来合理设计抗疟药物的努力。